Preventing and Treating Brain Metastases with Three First-Line EGFR-TKI in Patients with EGFR Mutation Advanced NSCLC

被引：0
|
作者：
Lin, C. [1 ]
Su, W. [1 ]
Wu, Y. [2 ]
机构：
[1] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[2] Natl Cheng Kung Univ Hosp, Dept Nursing, Tainan, Taiwan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
Brain metastasis; tyrosine kinase inhibitor; EGFR mutation;
D O I：
10.1016/j.jtho.2018.08.616
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-60
引用
收藏
页码：S484 / S484
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients with NSCLC Harboring Sensitive EGFR Mutations
    Yamada, Y.
    Imai, H.
    Sugiyama, T.
    Minemura, H.
    Kaira, K.
    Kanazawa, K.
    Kasai, T.
    Kaburagi, T.
    Minato, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S908 - S908
  • [32] The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study
    Liu, Yuting
    Wang, Juanjuan
    Wu, Jingjing
    Yang, Qifan
    Zeng, Yulan
    Wu, Di
    Tian, Chen
    Hu, Yue
    Gu, Feifei
    Li, Chang
    Zhang, Kai
    Liu, Li
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
  • [33] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
    da Silva, L. L.
    Matsas, S.
    Aguiar, P., Jr.
    Taveira, G. M. T.
    Barcelos, I. F.
    Lopes, G. L., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
  • [34] First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant Nsclc Patients with Oligoprogressive Disease
    Xu, Q.
    Liu, H.
    Hang, T.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S592 - S592
  • [35] T790M MUTATION ASSOCIATED WITH BETTER EFFICACY OF CONTINUOUS EGFR-TKI TREATMENT IN ADVANCED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
    Ren, Shengxiang
    Li, Wei
    Li, Aiwu
    Chen, Xiaoxia
    Gao, Guanghui
    He, Yayi
    Li, Xuefei
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1084 - S1084
  • [36] Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study
    He, Zhi-Yong
    Liu, Mei-Fang
    Lin, Jing-Hui
    Lin, Dong
    Lin, Ren-Jang
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 2129 - 2138
  • [37] Osimertinib (OSI) vs Standard of Care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
    Bischoff, H. G.
    Rueckert, A.
    Reinmuth, N.
    Grohe, C.
    Bohnet, S.
    zum Bueschenfelde, C. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 187 - 187
  • [38] Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFR mutated (EGFRm) advanced NSCLC: FLAURA China study overall survival (OS)
    Cheng, Y.
    He, Y.
    Li, W.
    Zhang, H-L.
    Zhou, Q.
    Wang, B.
    Liu, C.
    Walding, A.
    Saggese, M.
    Huang, X.
    Liu, Y.
    Su, R.
    Ramalingam, S. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S838 - S839
  • [39] Update Phase II Results of Early Primary Tumor Stereotactic Body Radiotherapy Combined with First-Line EGFR-TKI in Advanced EGFR Mutated NSCLC
    Lv, D.
    Xu, H.
    Meng, Y.
    Wang, W.
    Wu, X.
    Kong, F.
    Yang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S395 - S396
  • [40] Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
    Imamura, Fumio
    Inoue, Takako
    Kunimasa, Kei
    Kubota, Aki
    Kuhara, Hanako
    Tamiya, Motohiro
    Nishino, Kazumi
    Kimura, Madoka
    Kuno, Kika
    Kawachi, Hayato
    Kumagai, Toru
    LUNG CANCER MANAGEMENT, 2020, 9 (02)
12345